RESUMEN
In a randomized cross-over study the saluretic effect of furosemide-retard was compared with the combination of furosemide-retard/triamterene in 10 healthy male volunteers. The combination led to a significantly stronger excretion of sodium and a significantly lower excretion of potassium than furosemide-retard. The interaction of the saluretic with the antikaliuretic was even more distinctly expressed regarding sodium related quotients. The combination furosemide-retard/triamterene differs significantly from furosemide-retard in the main considering Na+/Cl-, Na+/K+ and Na+/Mg2+ quotients. The concentration time curves for furosemide and OH-TA-sulphate in the plasma are nearly similar. Maximal plasma levels for furosemide are reached after 3.9h and for OH-TA-sulphate after 2.2h. The 'apparent' elimination half-life time for furosemide is 2.1h and the elimination half-life time for OH-TA-sulphate is 2.0h.
Asunto(s)
Electrólitos/orina , Furosemida/farmacología , Triantereno/farmacología , Adulto , Preparaciones de Acción Retardada , Combinación de Medicamentos , Furosemida/farmacocinética , Humanos , Masculino , Triantereno/farmacocinéticaRESUMEN
The antihypertensive active of Xipamide was tested in 23 patients. Xipamide was given in combination with clonidine hydrochloride. The diuretic produced additional reductions in the recumbent blood pressure in 15 patients, and the orthostatic pressure in 19 patients. The antihypertensive action corresponds to those of established diuretics. The same responses were obtained in essential and secondary hypertension. A disadvantage associated with long-term treatment is that of hypokalaemia, which occurs at a dose level of 80 mg Xipamide (double the therapeutic dose). We accordingly recommend a dose of 40 mg, and, as a precaution, regular electrolyte checks. The levels of other side-effects-interference in carbohydrate, lipid, and uric acid metabolism and the rise in blood urea nitrogen are the same as for other diuretics.
Asunto(s)
Diuréticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Xipamida/uso terapéutico , Adulto , Glucemia/metabolismo , Presión Sanguínea/efectos de los fármacos , Nitrógeno de la Urea Sanguínea , Cloruros/sangre , Clonidina/administración & dosificación , Clonidina/uso terapéutico , Quimioterapia Combinada , Humanos , Lípidos/sangre , Potasio/sangre , Sodio/sangre , Factores de Tiempo , Ácido Úrico/sangre , Xipamida/administración & dosificación , Xipamida/farmacologíaAsunto(s)
Benzotiadiazinas , Diuréticos/efectos adversos , Metabolismo de los Lípidos , Inhibidores de los Simportadores del Cloruro de Sodio/efectos adversos , Xipamida/efectos adversos , Colesterol/sangre , Ésteres del Colesterol/sangre , Combinación de Medicamentos , Prueba de Tolerancia a la Glucosa , Glucosuria , Lípidos/sangre , Fosfolípidos/sangre , Triantereno/efectos adversos , Triglicéridos/sangre , Ácido Úrico/sangreRESUMEN
The spontaneous rossette-formation of lymphocytes and the rate of the DNA-synthesis was determined in 33 uremic patients of the haemodialysis unit. 1. Spontaneous rosette-formation of uremic lymphocytes (39,5%,n=16) did not differ from normal lymphocytes (39,3%,n=39). 2. The absolute lymphocyte count was slightly but not significantly reduced in uremic patients compared to normal controls and the slight increase after dialysis was not significant. 3. The PHA-induced DNA-synthesis of lymphocytes of 23 uremic patients was significantly reduced compared to normal controls. 4. The reduced PHA-induced DNA-synthesis of lymphocytes of uremic patients was not different in patients dialysed two times (22 hours) per week and patients dialysed three times (30 hours) per week. 5. No correlation of the reduction of PHA-induced DNA-synthesis to the underlying renal-diseases could be found.